Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced that Tolefi SA’s shares benefit from a double voting right as of May 3, 2021. As a result, the Company’s total number of voting rights is now 17,373,181.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures – Modified on 3 May 2021 following the Double Voting Rights:
|Total amount of share capital (EUR)
|Total Number of shares with single voting rights
|Total Number of shares with double voting rights
|Total Number of Shares
|Total of voting rights
|Total number of attributed warrants
|Total number of shares with voting rights that could be created following the exercise of the attributed warrants
|Total number of diluted shares (Outstanding shares + Warrants)
|Total number of diluted shares with voting rights
Contact person for regulated information (financial, transparency)
By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): firstname.lastname@example.org.
Further questions about the content of this release can be sent to email@example.com.